-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.
Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.
NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Q BioMed.
Mark had the pleasure of recently conducting the Interview featuring Denis D Corin, CEO and Chairman Q BioMed Inc. (OTCQB:QBIO). Mr. Roberts diligently focused on questions he thought would be on the minds of most current and potential future shareholders. See interview highlights below.
Access this interview in its entirety at
Denis D Corin
CEO and Chairman
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune -oncology company through 2014. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
Interview Highlights:
Traders News Source Editor Mark Roberts covers Strontium89 sales revenue, which of the preclinical stage products are expected to develop the fastest, QBIO portfolio of patents, patents pending and much more in this interview.
Access this interview in its entirety at
About Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Please visit and sign up for regular updates.
Q BioMed Media Contact:
Denis Corin
CEO
Investor Relations:
Keith Pinder
+1(404) 995-6671
ir@qbiomed.com
About Traders News Source (TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:
Media Contact
Traders News Source
Mark Roberts, Senior Editor/Interviewer Editor@TradersNewsSource.com
or Call Paul Lipp, President TNS LLC at +1-810-618-1023
SOURCE: Traders News Source LLC
View source version on accesswire.com:
NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Q BioMed.
紐約,NY/ACCESSWIRE/2022年8月25日/交易商新聞來源,一家領先的獨立股票研究和企業准入公司,專注於中小型上市公司,最近發佈了對Q BioMed的新的C級採訪。
Mark had the pleasure of recently conducting the Interview featuring Denis D Corin, CEO and Chairman Q BioMed Inc. (OTCQB:QBIO). Mr. Roberts diligently focused on questions he thought would be on the minds of most current and potential future shareholders. See interview highlights below.
馬克很高興最近採訪了Q BioMed Inc.(OTCQB:QBIO)首席執行官兼董事長丹尼斯·D·科林。羅伯茨勤奮地專注於他認為大多數當前和未來潛在股東都會考慮的問題。請看下面的採訪要點。
Access this interview in its entirety at
訪問此訪談全文,請訪問
Denis D Corin
丹尼斯·D·科林
CEO and Chairman
首席執行官兼董事長
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune -oncology company through 2014. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.
丹尼斯·D·科林先生是首席執行官兼董事會主席。科林先生是一位經驗豐富的上市公司高管和管理顧問。他幾乎完全在生物醫學領域工作了13年多,從大型製藥和診斷公司到小型創新生物技術公司。他曾擔任過各種高級管理職位,並在建立和重組業務方面發揮了重要作用。科林已經籌集了數百萬美元的發展資金,用於推動業務發展。科林先生還曾擔任TapImmune Inc.(NASD:TPIV)高管和董事會的管理顧問,該公司是一家臨牀階段免疫腫瘤學公司,一直到2014年。他擁有南非納塔爾大學經濟學和營銷與廣告管理專業的學士學位。
Interview Highlights:
面試要點:
Traders News Source Editor Mark Roberts covers Strontium89 sales revenue, which of the preclinical stage products are expected to develop the fastest, QBIO portfolio of patents, patents pending and much more in this interview.
Traders新聞來源編輯Mark Roberts報道了Strontium89的銷售收入,在這次採訪中,哪些臨牀前階段的產品有望開發出最快的QBIO專利組合、正在申請的專利等。
Access this interview in its entirety at
訪問此訪談全文,請訪問
About Q BioMed Inc.
關於Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Q BioMed Inc.是一家生物技術加速和商業階段公司。Q BioMed專注於許可和收購醫療行業被低估的生物醫療資產。Q BioMed致力於為這些目標資產提供所需的戰略資源、發展支持和擴張資本,以確保它們滿足其發展潛力,使它們能夠向需要的患者提供產品。
Please visit and sign up for regular updates.
請訪問並註冊以定期更新。
Q BioMed Media Contact:
問:BioMed媒體聯繫人:
Denis Corin
CEO
丹尼斯·科林
首席執行官
Investor Relations:
投資者關係:
Keith Pinder
+1(404) 995-6671
ir@qbiomed.com
基思·平德
+1(404) 995-6671
郵箱:ir@qbied.com
About Traders News Source (TNS)
關於交易商新聞來源(TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit:
交易員新聞來源是一家領先的獨立股票研究和企業訪問公司,專注於在重大舉措之前發現和報告下一個熱門股票和市場板塊。TNS也是一家金融新聞提供商,專注於讓投資者直接接觸有前途的上市公司的首席執行官和市場專家。我們的C層訪談回答了大多數當前和未來股東心中的一些尖鋭問題。TNS C級訪談為一些最有前途的中小型上市公司的運營和管理方向提供了寶貴的見解。要查看TNS披露聲明,請訪問:
Media Contact
媒體聯繫人
Traders News Source
交易員新聞來源
Mark Roberts, Senior Editor/Interviewer Editor@TradersNewsSource.com
高級編輯/採訪者編輯@TradersNewsSource.com
or Call Paul Lipp, President TNS LLC at +1-810-618-1023
或致電保羅·利普,總裁TNS LLC,電話:+1-810-618-1023
SOURCE: Traders News Source LLC
資料來源:交易員新聞來源有限責任公司
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧